250 related articles for article (PubMed ID: 37240419)
1. Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells.
Hellmold D; Kubelt C; Daunke T; Beckinger S; Janssen O; Hauck M; Schütt F; Adelung R; Lucius R; Haag J; Sebens S; Synowitz M; Held-Feindt J
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240419
[TBL] [Abstract][Full Text] [Related]
2. Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.
Caylioglu D; Meyer RJ; Hellmold D; Kubelt C; Synowitz M; Held-Feindt J
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808494
[TBL] [Abstract][Full Text] [Related]
3. Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model.
Adamski V; Schmitt C; Ceynowa F; Adelung R; Lucius R; Synowitz M; Hattermann K; Held-Feindt J
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1475-1485. PubMed ID: 29858681
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment of AT101 and demethoxycurcumin yields an enhanced anti-proliferative effect in human primary glioblastoma cells.
Mehner M; Kubelt C; Adamski V; Schmitt C; Synowitz M; Held-Feindt J
J Cancer Res Clin Oncol; 2020 Jan; 146(1):117-126. PubMed ID: 31844979
[TBL] [Abstract][Full Text] [Related]
5. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
6. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
7. WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
Ma Z; Cai S; Xiong Q; Liu W; Xia H; Zhu Z; Huang Z; Yan X; Wang Q
Apoptosis; 2022 Feb; 27(1-2):80-89. PubMed ID: 35037107
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a glioblastoma in vitro (in)complete resection dual co-culture model suitable for drug testing.
Schmitt C; Adamski V; Rasch F; Adelung R; Lucius R; Synowitz M; Hattermann K; Held-Feindt J
Ann Anat; 2020 Mar; 228():151440. PubMed ID: 31726206
[TBL] [Abstract][Full Text] [Related]
9. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
Zhao K; Schäfer A; Zhang Z; Elsässer K; Culmsee C; Zhong L; Pagenstecher A; Nimsky C; Bartsch JW
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008590
[TBL] [Abstract][Full Text] [Related]
11. TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
Yu J; Gao G; Wei X; Wang Y
BMC Cancer; 2022 Jul; 22(1):786. PubMed ID: 35850753
[TBL] [Abstract][Full Text] [Related]
12. AT101-Loaded Cubosomes as an Alternative for Improved Glioblastoma Therapy.
Flak DK; Adamski V; Nowaczyk G; Szutkowski K; Synowitz M; Jurga S; Held-Feindt J
Int J Nanomedicine; 2020; 15():7415-7431. PubMed ID: 33116479
[TBL] [Abstract][Full Text] [Related]
13. PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma.
Yang E; Wang L; Jin W; Liu X; Wang Q; Wu Y; Tan Y; Wang Y; Cui X; Zhao J; Tong F; Hong B; Xiao M; Liu X; Fang C; Kang C
Theranostics; 2022; 12(9):4330-4347. PubMed ID: 35673568
[No Abstract] [Full Text] [Related]
14. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
15. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract][Full Text] [Related]
16. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Su IC; Su YK; Setiawan SA; Yadav VK; Fong IH; Yeh CT; Lin CM; Liu HW
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175412
[TBL] [Abstract][Full Text] [Related]
17. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
18. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
Wang S; Chen C; Li J; Xu X; Chen W; Li F
J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273
[TBL] [Abstract][Full Text] [Related]
19. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
20. PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Zhou L; Huang X; Zhang Y; Wang J; Li H; Huang H
Brain Behav; 2022 May; 12(5):e2531. PubMed ID: 35380741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
